Bococizumab is a novel anti-PCSK9 antibody efficiently developed to treat hypercholesterolemia. This therapeutic agent interacts with the PCSK9 protein, a key regulator of cholesterol levels. By blocking the activity https://socialmediainuk.com/story26386137/bococizumab-a-novel-anti-pcsk9-antibody-for-hypercholesterolemia